Van Vollenhoven, Ronald F.Voskuyl, Alexandre E.Bertsias, GeorgeAranow, CynthiaAringer, MartinArnaud, LaurentAskanase, AncaBalá ová, PetraBonfa, EloisaBootsma, HendrikaBoumpas, DimitriosBruce, Ian N.Cervera i Segura, Ricard, 1960-Clarke, Ann E.Coney, CindyCostedoat-Chalumeau, NathalieCzirják, LászlóDerksen, R. H. W. M.Doria, AndreaDörner, ThomasFischer-Betz, RebeccaFritsch-Stork, RuthGordon, CarolineGraninger, WinfriedGyöri, NoémiHoussiau, Frédéric A.Isenberg, DavidJacobsen, SørenJayne, DavidKuhn, AnnegretLe Guern, VéroniqueLerstrøm, KirstenLevy, Roger A.Machado-Ribeiro, FrancinneMariette, XavierMissaykeh, JamilMorand, EricMosca, MartaInanc, MuratNavarra, Sandra2018-06-222018-06-222016-11-240003-4967https://hdl.handle.net/2445/123199Objectives Treat-to-target recommendations have identified 'remission' as a target in systemic lupus erythematosus (SLE), but recognise that there is no universally accepted definition for this. Therefore, we initiated a process to achieve consensus on potential definitions for remission in SLE. Methods An international task force of 60 specialists and patient representatives participated in preparatory exercises, a face-to-face meeting and follow-up electronic voting. The level for agreement was set at 90%. Results The task force agreed on eight key statements regarding remission in SLE and three principles to guide the further development of remission definitions: 1. Definitions of remission will be worded as follows: remission in SLE is a durable state characterised by . (reference to symptoms, signs, routine labs). 2. For defining remission, a validated index must be used, for example, clinical systemic lupus erythematosus disease activity index (SLEDAI)=0, British Isles lupus assessment group (BILAG) 2004 D/E only, clinical European consensus lupus outcome measure (ECLAM)=0; with routine laboratory assessments included, and supplemented with physician's global assessment. 3. Distinction is made between remission off and on therapy: remission off therapy requires the patient to be on no other treatment for SLE than maintenance antimalarials; and remission on therapy allows patients to be on stable maintenance antimalarials, low-dose corticosteroids (prednisone ≤5 mg/day), maintenance immunosuppressives and/or maintenance biologics. The task force also agreed that the most appropriate outcomes (dependent variables) for testing the prognostic value (construct validity) of potential remission definitions are: death, damage, flares and measures of health-related quality of life. Conclusions The work of this international task force provides a framework for testing different definitions of remission against long-term outcomes.8 p.application/pdfeng(c) BMJ Publishing Group, 2016Lupus eritematósMalalties autoimmunitàriesFarmacologiaEstudi de casosLupus erythematosusAutoimmune diseasesPharmacologyCase studiesinfo:eu-repo/semantics/article6786102018-06-22info:eu-repo/semantics/openAccess27884822